Treatment of peri-implantitis using platelet-rich fibrin
Surgical Treatment of Peri-implantitis With Adjunctive Application of Platelet Rich Fibrin (PRF) Compared With Open Flap Debridement (OFD) Alone: A 12-month Randomised Clinical Trial
NA · University of Bern · NCT06679283
This study is testing whether adding platelet-rich fibrin to surgery can help people with peri-implantitis heal better and improve bone growth around their dental implants.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Bern (other) |
| Drugs / interventions | prednisone |
| Locations | 1 site (Bern) |
| Trial ID | NCT06679283 on ClinicalTrials.gov |
What this trial studies
This study investigates the effectiveness of platelet-rich fibrin (PRF) in enhancing the surgical treatment of peri-implantitis, a condition characterized by inflammation and bone loss around dental implants. Participants will undergo open flap debridement either with the adjunctive application of PRF or without it, allowing for a comparison of outcomes. The study aims to assess improvements in bone regeneration and healing in patients with peri-implantitis defects. By evaluating the impact of PRF on treatment outcomes, the research seeks to provide evidence for its use in clinical practice.
Who should consider this trial
Good fit: Ideal candidates include adults with peri-implantitis characterized by specific clinical and radiographic criteria.
Not a fit: Patients with severe systemic diseases, chronic inflammatory conditions, or those who smoke more than five cigarettes may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved healing and regeneration in patients suffering from peri-implantitis, potentially reducing the need for more invasive treatments.
How similar studies have performed: While some studies have shown positive effects of PRF in bone regeneration, evidence specifically for its use in peri-implantitis remains limited, making this approach somewhat novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. One or more peri-implant sites with PPD ≧ 5 mm combined with BOP/suppuration and 2. Peri-implant marginal bone loss, defined as a crater like defect ≧ 3 mm as assessed from intraoral radiographs 3. Good oral hygiene i.e. a plaque index \<20% 4. Written informed consent Exclusion Criteria: 1. History of chronic inflammatory disease 2. Severe systemic diseases 3. Medically confirmed diagnosis of diabetes mellitus 4. Anti-inflammatory prescription including prednisone 5. Smoking \> 5 cigarettes 6. Pregnant or lactating women 7. \< 18 years of age
Where this trial is running
Bern
- Department of Periodontology, University of Bern — Bern, Switzerland (RECRUITING)
Study contacts
- Principal investigator: Giovanni Salvi, MD — University of Bern
- Study coordinator: Alexandra Stähli, MD
- Email: alexandra.staehli@unibe.ch
- Phone: +41316840727
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Peri-Implantitis, Bone Resorption, Platelet-Rich Fibrin, platelet rich fibrin, peri-implantitis